Inhibition of MyBP-C binding to myosin as a treatment for heart failure
The present invention provides for methods of treating and slowing the onset of heart failure. The inventors have determined that myosin binding to unphosphorylated Myosin Binding Protein C (MyBP-C) plays a key role in the diminution of cardiac contractile force and frequency in heart failure. The present invention provides peptide inhibitors of the MyBP-C/myosin interaction, thereby increasing both cardiac contractile force and frequency in the failing heart, as well as in patients not yet exhibiting frank heart failure.
1. A method of treating heart failure comprising:
(a) identifying a patient exhibiting one or more symptoms of heart failure; and
(b) administering to said patient a peptide of no more than 50 residues that comprises the MyBP-C binding site for myosin and binds to myosin and comprises the sequence LKKRDXFRRD (SEQ ID NO: 1), where X is A, V or D.
2. The method of claim 1 , wherein administering the peptide is performed intramuscularly, intravenously or by direct injection into cardiac tissue.
3. The method of claim 1 , wherein administering the peptide comprises oral, transdermal, sustained release, controlled release, delayed release, suppository, or sublingual administration.
4. The method of claim 1 , further comprising administering to said patient a second heart failure therapy.
5. The method of claim 4 , wherein said second therapy is selected from the group consisting of a beta blocker, an ionotrope, a diuretic, ACE-I, AII antagonist, BNP, or a Ca ++ channel blocker.
6. The method of claim 4 , wherein said second therapy is administered at the same time as said peptide.
7. The method of claim 4 , wherein said second therapy is administered either before or after said peptide.
8. The method of claim 1 , wherein treating comprises improving one or more symptoms of heart failure.
9. The method of claim 8 , wherein said one or more improved symptoms comprises increased exercise capacity, increased cardiac ejection volume, increased cardiac ejection fraction, decreased left ventricular end diastolic pressure, decreased pulmonary capillary wedge pressure, increased cardiac output, or cardiac index, lowered pulmonary artery pressures, decreased left ventricular end systolic and diastolic dimensions, decreased left and right ventricular wall stress, decreased wall tension, increased quality of life, and decreased disease-related morbidity or mortality.
10. The method of claim 1 , wherein the peptide comprises the sequence FSSLLKKRDXFRRD (SEQ ID NO: 48), FSSLLKKRDXFRRDXK (SEQ ID NO: 49), LKKRDXFRRDXKLE (SEQ ID NO: 50), SLLKKRDXFRRDXKLE (SEQ ID NO: 51), FSSLLKKRDXFRRDXKLE (SEQ ID NO: 52), or SLLKKRDAFRRDAKLE (SEQ ID NO: 53).
11. The method of claim 1 , wherein said peptide is no more than 25, 30, 35, 40 or 45 residues.
12. The method of claim 1 , wherein said peptide comprises a cell penetrating domain.
13. The method of claim 1 , wherein said peptide comprises some or all D-amino acids.
14. A method of slowing the progression of heart failure comprising:
(a) identifying a patient at risk of developing severe heart failure; and
(b) administering to said patient a peptide of no more than 50 residues that comprises the MyBP-C binding site for myosin and binds to myosin and comprises the sequence LKKRDXFRRD (SEQ ID NO: 1), where X is A, V or D.
15. The method of claim 14 , wherein the patient at risk may exhibit one or more of a list of risk factors comprising long-standing uncontrolled hypertension, uncorrected valvular disease, chronic angina, recent myocardial infarction, congenital predisposition to heart disease or pathological hypertrophy.
16. The method of claim 14 , wherein the patient at risk may be diagnosed as having a genetic predisposition to heart failure.
17. The method of claim 14 , wherein the patient at risk may have a familial history of heart failure.
18. The method of claim 14 , further comprising administering to said patient a second heart failure therapy.
19. The method of claim 18 , wherein said second therapy is selected from the group consisting of a beta blocker, an ionotrope, a diuretic, ACE-I, AII antagonist, BNP, or a Ca ++ channel blocker.
20. The method of claim 14 , wherein said subject is a heart transplant recipient.
21. The method of claim 14 , wherein the peptide comprises the sequence FSSLLKKRDXFRRD (SEQ ID NO: 48), FSSLLKKRDXFRRDXK (SEQ ID NO: 49), LKKRDXFRRDXKLE (SEQ ID NO: 50), SLLKKRDXFRRDXKLE (SEQ ID NO: 51), FSSLLKKRDXFRRDXKLE (SEQ ID NO: 52), or SLLKKRDAFRRDAKLE (SEQ ID NO: 53).
22. The method of claim 14 , wherein said peptide is no more than 25, 30, 35, 40 or 45 residues.
23. The method of claim 14 , wherein said peptide comprises a cell penetrating domain.
24. The method of claim 14 , wherein said peptide comprises some D-amino acids.